Dendritic cell surface membrane (DC membrane)

The dendritic cell surface membrane is the outer lipid bilayer of dendritic cells, serving as the critical interface between these professional antigen-presenting cells and the external environment (Worbs et al., 2017, Nature Reviews Immunology). It is not a single molecular target but rather a complex cellular structure that houses a diverse array of proteins essential for immune surveillance, including pattern recognition receptors (PRRs), major histocompatibility complex (MHC) molecules, and costimulatory proteins (Banchereau et al., 2000, Nature). These membrane-bound components facilitate the capture of antigens and the subsequent activation of T cells, bridging the innate and adaptive immune systems (Roche & Furuta, 2015, Nature Reviews Immunology). In clinical practice, the membrane is the site of action for various immunotherapies, such as TLR agonists and checkpoint modulators, which aim to enhance anti-tumor immunity or induce tolerance in autoimmune conditions (Wculek et al., 2020, Nature Reviews Immunology). For example, the DC-based vaccine Sipuleucel-T involves the manipulation of these cells to treat prostate cancer (Kantoff et al., 2010, NEJM). Because it is a cellular compartment rather than a specific protein, it is considered an 'incorrect' target designation for precise molecular drug discovery, which instead focuses on individual receptors located upon this membrane.

Other names

Dendritic cell plasma membraneDC surfaceDendritic cell membrane

Drugs typically modulate immune activity by binding to specific receptors or proteins embedded within the dendritic cell surface membrane, such as Toll-like receptors (TLRs), C-type lectin receptors, or costimulatory molecules (CD80/CD86), to either stimulate or suppress the immune response.